Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Avior Wealth Management LLC

Avior Wealth Management LLC trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,664 shares of the medical equipment provider’s stock after selling 238 shares during the quarter. Avior Wealth Management LLC’s holdings in Lantheus were worth $622,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Signaturefd LLC boosted its holdings in shares of Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares in the last quarter. Silverberg Bernstein Capital Management LLC boosted its stake in Lantheus by 0.4% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after acquiring an additional 100 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 146 shares in the last quarter. Finally, Moody National Bank Trust Division lifted its holdings in shares of Lantheus by 1.1% in the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock valued at $1,203,000 after purchasing an additional 162 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on LNTH shares. Truist Financial reaffirmed a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday. Redburn Atlantic started coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. JMP Securities reduced their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. Finally, B. Riley raised their price target on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Stock Up 1.0 %

Shares of Lantheus stock opened at $87.32 on Friday. The firm has a market cap of $6.07 billion, a price-to-earnings ratio of 14.53 and a beta of 0.51. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The company’s 50-day simple moving average is $103.76 and its 200-day simple moving average is $96.59.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.